Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention-Reference-Cited by-同舟云学术

Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention

Published:2016-04-26 Issue:16 Volume:315 Page:1735
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Yeh Robert W.¹,Secemsky Eric A.²,Kereiakes Dean J.³,Normand Sharon-Lise T.⁴,Gershlick Anthony H.⁵,Cohen David J.⁶,Spertus John A.⁷,Steg Philippe Gabriel⁸,Cutlip Donald E.⁹,Rinaldi Michael J.¹⁰,Camenzind Edoardo¹¹,Wijns William¹²,Apruzzese Patricia K.¹³,Song Yang¹³,Massaro Joseph M.¹⁴,Mauri Laura¹⁵,

Affiliation:

1. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts2Harvard Medical School, Boston, Massachusetts3Harvard Clinical Research Institute, Boston, Massachusetts

2. Harvard Medical School, Boston, Massachusetts3Harvard Clinical Research Institute, Boston, Massachusetts4Cardiology Division, Massachusetts General Hospital, Boston

3. Christ Hospital Heart and Vascular Center, Cincinnati, Ohio6Lindner Center for Research and Education, Cincinnati, Ohio

4. Harvard Medical School, Boston, Massachusetts7Harvard T. H. Chan School of Public Health, Boston, Massachusetts

5. Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom9National Institute for Health Research Leicester Cardiovascular Biomedical Research Unit, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester,

6. Saint Luke’s Mid America Heart Institute, Kansas City, Missouri11University of Missouri-Kansas City School of Medicine, Kansas City, Missouri

7. Saint Luke’s Mid America Heart Institute, Kansas City, Missouri11University of Missouri-Kansas City School of Medicine, Kansas City, Missouri12Washington University in St Louis, School of Medicine, St Louis, Missouri

8. Université Paris-Diderot, INSERM U-1148, Hôpital Bichat, Paris, France14Département Hospitalo-Universitaire Fibrosis, Inflammation, and Remodeling, Assistance Publique, Hôpitaux de Paris, Paris, France15National Heart and Lung Institute, Institute of Card

9. Harvard Medical School, Boston, Massachusetts3Harvard Clinical Research Institute, Boston, Massachusetts16Beth Israel Deaconess Medical Center, Boston, Massachusetts

10. Sanger Heart and Vascular Institute, Carolinas HealthCare System, Charlotte, North Carolina

11. Institut Loraine du Coeur et des Vaisseaux, University Hospital of Nancy-Brabois, Vandoeuvre-les-Nancy, France

12. Cardiovascular Center, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium

13. Harvard Clinical Research Institute, Boston, Massachusetts

14. Harvard Clinical Research Institute, Boston, Massachusetts20Boston University School of Public Health, Boston, Massachusetts

15. Harvard Medical School, Boston, Massachusetts3Harvard Clinical Research Institute, Boston, Massachusetts21Brigham and Women’s Hospital, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 804 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Considerations in Antiplatelet Therapy in Women Undergoing Treatment of Acute Coronary Syndrome or Percutaneous Coronary Intervention;Interventional Cardiology Clinics;2024-10

2. Antithrombotic Therapy in Patients with Chronic Coronary Syndromes;Interventional Cardiology Clinics;2024-10

3. High Bleeding Risk in Patients Undergoing Coronary and Structural Heart Interventions;Interventional Cardiology Clinics;2024-10

4. 2023 European Society of Cardiology guidelines for the management of acute coronary syndromes;Netherlands Heart Journal;2024-09-10

5. Should We Use Aspirin or P2Y12 Inhibitor Monotherapy in Stable Ischemic Heart Disease?;Current Atherosclerosis Reports;2024-09-07